Pepbase

VIP

Also known as: Vasoactive Intestinal Peptide, Aviptadil

Not FDA Approved
Immune SupportCognitiveHealth

Primary use: Inflammatory condition support

ℹ️

What is VIP?

Vasoactive Intestinal Peptide (VIP) is a naturally occurring neuropeptide with a 28-amino acid sequence that has potent anti-inflammatory, immunomodulatory, and neuroprotective properties. It binds to VPAC1 and VPAC2 receptors, affecting immune function, vascular tone, and neurological health. VIP is being studied for applications in conditions such as chronic inflammatory response syndrome, pulmonary disorders, and COVID-19 related ARDS. Although VIP is not approved by the FDA, it has received Fast Track designation for specific indications, but users should be cautious of potential side effects like nausea and blood pressure changes.

Primary Benefits
  • Reduces inflammation
  • Neuroprotective effects
  • Improves respiratory health
How It Works

VIP binds to VPAC1 and VPAC2 receptors, activating adenylate cyclase and increasing cAMP/PKA signaling. This cascade results in anti-inflammatory effects, vasodilation, and modulation of T-cell functions. Intranasal delivery allows direct CNS access via olfactory pathways.

⚠️

Safety Tips

Precautions reported in community discussions and literature. This is not a complete list. View Full Side Effects Guide →
  • 1DON'T exceed recommended dosing - maintain within 50-100 mcg daily.
  • 2NEVER use VIP if you are pregnant or breastfeeding.
  • 3AVOID using VIP if you have a known sensitivity to it or any of its components.
  • 4DON'T store VIP outside of recommended conditions - keep refrigerated at 2-8°C.
  • 5NEVER use without medical supervision, especially if managing conditions like CIRS.

Who Should NOT Use

  • Pregnancy
  • Breastfeeding
  • Known allergic reactions to peptide components

Dosage & Protocols

Different purposes have different protocols, dosing, and considerations

💉

Chronic Inflammatory Response Syndrome (CIRS)

moderate evidence

Used in protocols for inflammatory marker correction in CIRS patients, often after completing other stages of treatment protocols.

Evidence: Studies show correction of inflammatory markers with ongoing treatment in inflammatory conditions.

The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.

Range
50-100 mcg
Frequency
twice daily
Cycle
4-12 weeks
Route
Intravenous, Intramuscular, Intravenous
TimingMorning and evening
NotesDosing varies by protocol, continuation should be guided by medical supervision.

📋Community-Reported Protocols

Not recommendations:

The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.

Reported GoalReported DoseReported FrequencyReported Route
CIRS correction50mcg per spray4x dailyIntranasal

⏱️Pharmacokinetics

Half-Life
30 min
Time to Peak
15 min
Clearance
2.5 hours

⚡Reported Side Effects

This is not a complete list. Other side effects may occur.

Common
Nauseacommon (1-10%)
Dizzinesscommon (1-10%)
Serious / Rare
  • • Elevated TGF-β1
  • • Lipase elevation
Injection-Specific Warnings
  • Injection site reactions
  • Sterile technique required

🧊Storage

Temperature
2-8°C
Reconstituted
2-8°C
Shelf Life
Various, based on compounding
Light Sensitive
Yes - protect from light
💉

Pulmonary disorders including COVID-19 ARDS

moderate evidence

Fast Track designation for COVID-19 ARDS; explored in related pulmonary issues.

Evidence: Early-stage trials have shown potential supportive effects in ARDS by stabilizing inflammatory markers and enhancing patient outcomes.

The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.

Range
50-100 mcg/kg
Frequency
twice daily
Cycle
2-6 weeks
Route
Intravenous
TimingAs directed
NotesHigh supervision required due to study setting; dosing tends to be intravenous in clinical contexts.

⏱️Pharmacokinetics

Half-Life
30 min
Time to Peak
15 min
Clearance
2.5 hours

⚡Reported Side Effects

This is not a complete list. Other side effects may occur.

Common
Blood pressure decreasecommon (1-10%)
Serious / Rare
  • • Respiratory difficulty in high doses

🧊Storage

Temperature
Room temperature
Reconstituted
N/A
Shelf Life
As per clinical insertion
Light Sensitive
Yes - protect from light
🛡️

Harm Reduction Information

Quality Concerns

  • Possible contamination if sourced from unregulated suppliers
  • Potential for mislabeling of concentration in compounded forms

Safety Tips

  • Use bacteriostatic water for reconstitution
  • Employ sterile techniques for all formulations
  • Start with a lower dose to evaluate tolerance
  • Rotate nasal spray nostrils to prevent irritation
  • Regular monitoring of vital signs when under treatment

Warning Signs to Stop

  • Severe headache
  • Rapid heart rate
  • Severe dizziness

Seek Medical Help Immediately If

  • Developing symptoms of respiratory distress
  • Uncontrolled bleeding
  • Severe allergic reactions
❓

Frequently Asked Questions

How long until I see effects?

Effects of VIP, especially for inflammation, may be noticed within days to weeks, but full results can take months, particularly in cases like CIRS.

What time of day should I take it?

VIP is best taken in the morning or as directed by treatment goals, as it aligns with natural circadian rhythms.

How can I minimize side effects?

To minimize side effects of VIP, start with lower doses and ensure you are under medical supervision especially for conditions like chronic inflammatory response syndrome.

Does tolerance develop?

Tolerance to VIP is not widely reported, but continuous monitoring with medical guidance is recommended to adjust dosing as needed.

How should I store it?

Store VIP in a refrigerator at 2-8°C and ensure it's compounded correctly if using nasal spray formulations.

Do I need to cycle it?

Cycling of VIP use may depend on the specific condition being treated, but some protocols allow continuous usage under medical supervision.

🔄

Reported Combinations

Compounds reported to be used alongside VIP in community discussions. Not a recommendation.

investigational

BPC-157

Addresses tissue repair alongside anti-inflammatory actions.

investigational

Thymosin Alpha-1

Immune modulation enhancement.

investigational

GHK-Cu

Enhanced skin and respiratory tissue repair.

⚠️

Reported Interactions

Interactions reported in literature and community discussions.

NSAIDsmoderate

May increase risk of gastrointestinal discomfort.

Beta-blockersmajor

Can enhance vasodilatory effect, potentially leading to hypotension.

Antidepressantsminor

Minor interaction, but monitor for any mood changes.

Reconstitution Guide

Reconstitution Calculator

mL
U100 insulin syringe01020304050607080901001mL

100 units = 1 mL

Safety Tips

  • Always consult a licensed medical professional for dosing and reconstitution instructions.
  • Always double check your units. Mixing up mg and mcg can be very dangerous.
  • Make sure to select your syringe type. U-100 and U-50 syringes have different units.
  • Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.

This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.

Explore More Research

Browse our database of peptide research information compiled from published literature and community sources.

Browse All PeptidesAbout Pepbase App
📚

Other Sources & Citations

PubMed
Vip And Inflammatory Bowel...
pmc.ncbi.nlm.nih.gov•Updated Jan 2026
frontiersin
Frontiers | Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
frontiersin.org•Updated Apr 2025
PubMed
A Clinical Approach for the Use of VIP Axis in Inflammatory ...
pmc.ncbi.nlm.nih.gov•Updated Jan 2026
PubMed
Vasoactive intestinal peptide as a new drug for treatment of primary ...
pmc.ncbi.nlm.nih.gov•Updated Jan 2026

Last updated: October 21, 2023

Important Disclaimer

AI-Generated Content Notice

The information on this page has been compiled using artificial intelligence (AI) and large language model (LLM) technology from multiple sources including published literature, online communities, and public databases. This content may contain errors, inaccuracies, outdated information, or omissions. We make no guarantees regarding the accuracy, completeness, or reliability of any information presented. You are solely responsible for independently verifying any information before relying on it.

Not Medical Advice

Nothing on this website constitutes medical advice, diagnosis, or treatment recommendations. The information provided is for educational and harm-reduction purposes only. We do not provide individualized dosing guidance or treatment recommendations. Protocols and dosing information shown represent reports from community discussions and published literature—they are not endorsements or recommendations. Always consult with a licensed healthcare professional before making any health-related decisions.

No Endorsement of Use

Pepbase does not endorse, encourage, or recommend the use of any peptide or substance discussed on this website. Many compounds discussed are not approved for human use by the FDA or other regulatory agencies. Some substances may be illegal to possess, sell, or use in your jurisdiction. We do not facilitate or encourage the procurement, distribution, or use of controlled or prescription-only substances. Users are solely responsible for understanding and complying with all applicable laws in their jurisdiction.

Calculators and Tools

Any calculators, estimators, or tools provided on this website are for informational purposes only and produce estimates that may be inaccurate. Errors in calculations can result in serious harm. You are solely responsible for verifying all calculations independently. These tools do not account for individual factors that may affect dosing and should never be relied upon as a substitute for professional medical guidance.

Assumption of Risk

By using this website, you acknowledge that you understand the risks associated with using unregulated substances and that you assume full responsibility for your own health decisions. Pepbase, its creators, contributors, and affiliates disclaim all liability for any harm, injury, or damages arising from the use or misuse of information on this website. Use of any information on this site is entirely at your own risk.

If you are experiencing a medical emergency, call emergency services immediately. If you have questions about medications or supplements, consult a licensed pharmacist or physician.

Pepbase — Your peptide companion

© 2026 Pepbase. All rights reserved.